GAITHERSBURG, Md., April 10, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) announces the appointment of Paul D. Mintz, MD, Senior Vice President and Chief Medical Officer of Verax Biomedical, to its board of directors, effective April 7, 2017. The Company also announces Joseph Del Guercio is leaving the board due to his expanded responsibilities as President and CEO of the Clark Charitable Foundation, and will serve as an informal board advisor. With these changes, the size of the Nuo board remains at five directors.

Prior to joining Verax Biomedical in early 2016, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration. Prior to that, for more than 30 years Dr. Mintz was a member of the faculty of the University of Virginia School of Medicine, where he was a tenured Professor of Pathology and Internal Medicine. He also served as Vice-Chair of Pathology and Chief of the Division of Clinical Pathology, and as Medical Director of the Clinical Laboratories and Transfusion Medicine Services at the University of Virginia Health System. In addition, Dr. Mintz served as Co-Medical Director of Virginia Blood Services.

“It is a pleasure to welcome Paul to the Nuo board. His considerable knowledge of platelet biology and transfusion medicine, along with his senior regulatory and reimbursement experience, will be enormously valuable as we strive to advance the Aurix System toward broader commercialization in the large and growing chronic wound care market,” commented David Jorden, Chief Executive and Chief Financial Officer of Nuo. "We would like to thank Joe Del Guercio for his years of service to Nuo and appreciate his willingness to assume a board advisory role as we move forward to achieve our corporate goals.”

Dr. Mintz is a former President of the American Association of Blood Banks (AABB), served on the AABB’s Board of Directors for nine years, and was a member of and chaired numerous AABB committees. Dr. Mintz is a recipient of the AABB’s John Elliott Memorial Award. He has also served as a member of the Board of Trustees of the National Blood Foundation. A recipient of a Transfusion Medicine Academic Award from the National Heart, Lung and Blood Institute, Dr. Mintz was an inaugural inductee into the National Blood Foundation Hall of Fame. He has served as a member of the Medicare Coverage Advisory Committee of the Centers for Medicare and Medicaid Services (CMS).

“It is an honor to be joining the Nuo Board, in particular at this important point in the Company’s development. I look forward to working with my fellow directors to provide strategic insight and guidance throughout the process of CMS’ Clinical Evidence Development registry program to obtain broad-based payment for the Aurix System in the treatment for chronic wounds,” said Dr. Mintz.

Dr. Mintz is author or co-author of more than 100 articles and editorials spanning clinical practice, blood safety and the evaluation of new transfusion medicine technologies, and has designed and served as principal investigator for numerous clinical trials. He is the sole editor of all three editions of Transfusion Therapy: Clinical Principles and Practice (AABB Press) and has served on several journal editorial boards.

Dr. Mintz earned his BA in Philosophy from the University of Rochester and received his MD with honors from the University of Rochester School of Medicine.

About Nuo Therapeutics

Nuo Therapeutics, Inc. is a biomedical company offering biodynamic therapies for wound care. The Company's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. For additional information, please visit www.nuot.com or www.aurixsystem.com.